Quoin Pharmaceuticals
QNRX
2 hedge funds and large institutions have $937K invested in Quoin Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.
49% more capital invested
Capital invested by funds: $630K → $937K (+$307K)
33% less funds holding
Funds holding: 3 → 2 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$195K |
| 2 |
Renaissance Technologies
New York
|
+$97.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$60K |
| 2 |
HF
HRT Financial
New York
|
-$48K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$31K |
QNRX Hedge Fund Activity: Q3 2021 in Review
2 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q3 2021, worth a combined $937K — up 49% from $630K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of QNRX and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $195K. The largest seller was Citadel Advisors, exiting entirely with an estimated $60K sold.
- 2 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q3 2021, down from 3 in Q2 2021.
- Funds reported $937K of Quoin Pharmaceuticals stock for Q3 2021, up 49% quarter-over-quarter.
- 1 fund opened new Quoin Pharmaceuticals positions in Q3 2021 and 2 closed out, a net change of -1 holder.
- The largest Quoin Pharmaceuticals buyer in Q3 2021 was Geode Capital Management, an estimated $195K added.
- The largest Quoin Pharmaceuticals seller in Q3 2021 was Citadel Advisors, an estimated $60K sold.
Based on aggregated 13F filings for Q3 2021.